Overview

Study to Assess Efficacy and Safety of Bulevirtide in Patients With CHD

Status:
Active, not recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of bulevirtide for treatment of chronic hepatitis delta (CHD) in comparison to delayed treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
MYR GmbH
Collaborator:
Hepatera Ltd.